Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial
BM Everett, JG MacFadyen, T Thuren, P Libby… - Journal of the American …, 2020 - jacc.org
Background Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab
significantly reduces the first major adverse cardiovascular event in patients with prior …
significantly reduces the first major adverse cardiovascular event in patients with prior …
Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
BM Everett, JG MacFadyen, T Thuren… - Journal of the …, 2020 - europepmc.org
Background Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab
significantly reduces the first major adverse cardiovascular event in patients with prior …
significantly reduces the first major adverse cardiovascular event in patients with prior …
[引用][C] Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial
BM Everett, JG MacFadyen, T Thuren, P Libby… - Journal of the American …, 2020 - cir.nii.ac.jp
Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the
CANTOS Trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
CANTOS Trial | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[PDF][PDF] Inhibition of Interleukin-1b and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial
BM Everett, JG MacFadyen, T Thuren… - JOURNAL OF THE …, 2020 - isoic.org
ABSTRACT BACKGROUND Inflammation reduction with the interleukin (IL)-1b inhibitor
canakinumab significantly reduces the first major adverse cardiovascular event in patients …
canakinumab significantly reduces the first major adverse cardiovascular event in patients …
[HTML][HTML] Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial
BM Everett, JG MacFadyen, T Thuren, P Libby… - Journal of the American …, 2020 - Elsevier
Background Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab
significantly reduces the first major adverse cardiovascular event in patients with prior …
significantly reduces the first major adverse cardiovascular event in patients with prior …
Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial
BM Everett, JG MacFadyen, T Thuren, P Libby… - 2020 - pubmed.ncbi.nlm.nih.gov
Background Inflammation reduction with the interleukin (IL)-1β inhibitor canakinumab
significantly reduces the first major adverse cardiovascular event in patients with prior …
significantly reduces the first major adverse cardiovascular event in patients with prior …